Get the Stockscreener App
1.50
1.96%
-0.03
After Hours:
1.49
-0.01
-0.67%
Cocrystal Pharma Inc stock is traded at $1.50, with a volume of 315.73K.
It is down -1.96% in the last 24 hours and up +45.63% over the past month.
Cocrystal Pharma Inc is a biotechnology company discovering and developing novel antiviral therapeutics that target the replication machinery of influenza viruses, hepatitis C viruses, and noroviruses. It employs structure-based technologies and Nobel Prize-winning expertise to create first and in-class antiviral drugs. It is developing CC-31244, an investigational, oral, broad-spectrum replication inhibitor called a non-nucleoside inhibitor (NNI). The company has one reportable and operating segment dedicated to the research and development company's novel orally administered antiviral influenza candidate. The company has pipeline products for diseases like : Influenza, Norovirus, Coronavirus, Respiratory Viruses, and Hepatitis C.
See More
Previous Close:
$1.53
Open:
$1.5
24h Volume:
315.73K
Relative Volume:
0.14
Market Cap:
$20.68M
Revenue:
-
Net Income/Loss:
$-8.83M
P/E Ratio:
-1.8973
EPS:
-0.7906
Net Cash Flow:
$-8.61M
1W Performance:
+4.17%
1M Performance:
+45.63%
6M Performance:
+42.86%
1Y Performance:
+11.94%
1-Day Range:
$1.4601
$1.54
1-Week Range:
$1.17
$1.54
52-Week Range:
$0.8588
$2.67
Cocrystal Pharma Inc Stock (COCP) Company Profile
Name
Cocrystal Pharma Inc
Sector
Industry
Phone
(786) 459-1831
Address
19805 N. CREEK PARKWAY, BOTHELL, WA
Compare COCP vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
COCP
Cocrystal Pharma Inc
|
1.50 | 21.09M | 0 | -8.83M | -8.61M | -0.7906 |
VRTX
Vertex Pharmaceuticals Inc
|
441.70 | 113.01B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
753.93 | 79.87B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
840.87 | 51.51B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
333.39 | 45.29B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
319.94 | 34.41B | 5.36B | 287.73M | 924.18M | 2.5229 |
Cocrystal Pharma Inc Stock (COCP) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-08-20 | Initiated | H.C. Wainwright | Buy |
Cocrystal Pharma Inc Stock (COCP) Latest News
Smart Money: Can Cocrystal Pharma Inc deliver consistent EPS growth2026 Technical Patterns & Daily Growth Stock Tips - baoquankhu1.vn
Why Cocrystal Pharma Shares Are Cooling Off Monday? - MSN
COCP stock soars 75% — what is the link to Cocrystal’s norovirus treatment? - MSN
Investor Mood: Is Cocrystal Pharma Inc benefiting from innovation trendsQuarterly Risk Review & Advanced Swing Trade Entry Alerts - baoquankhu1.vn
Tech Rally: Is Cocrystal Pharma Inc stock risky to hold nowMarket Activity Summary & Consistent Profit Trading Strategies - baoquankhu1.vn
COCP: Fast Track Designation for CDI-988 for Norovirus Infection Treatment and Prevention - Zacks Small Cap Research
Cocrystal Pharma, Inc. (COCP) stock price, news, quote and history - Yahoo Finance UK
COCP PE Ratio & Valuation, Is COCP Overvalued - Intellectia AI
We're Keeping An Eye On Cocrystal Pharma's (NASDAQ:COCP) Cash Burn Rate - Yahoo Finance
Shares +48% after hours: COCP Cocrystal Pharma NASDAQ 03 Apr earnings spotlight - meyka.com
12 Health Care Stocks Moving In Thursday's Intraday Session - Sahm
12 Health Care Stocks Moving In Thursday's Pre-Market Session - Sahm
Crude Oil Rises Sharply; Acuity Shares Fall After Q2 Results - Sahm
Nasdaq Down 1%; US Initial Jobless Claims Fall - Sahm
Cocrystal Pharma Shares Soar After FDA Grants Fast Track Status To CDI-988 - Sahm
FDA grants fast track status to Cocrystal’s norovirus drug By Investing.com - Investing.com Australia
Cocrystal Pharma stock surges on FDA Fast Track designation By Investing.com - Investing.com South Africa
Cocrystal Pharma (COCP) Receives FDA Fast Track Status for Norov - GuruFocus
Cocrystal Pharma stock surges on FDA Fast Track designation - Investing.com
Cocrystal Pharma, Inc. (8CC.F) stock price, news, quote and history - Yahoo Finance UK
Cocrystal Pharma Advances in Norovirus Study as Financial Challenges Loom - StocksToTrade
Cocrystal Pharma Wins FDA Fast Track for Norovirus Drug - TipRanks
COCP Stock Soars 75% — What Is The Link To Cocrystal’s Norovirus Treatment? - Stocktwits
Cocrystal Pharma Advances Antiviral Trials Amid Financial Strategy Shift - timothysykes.com
FDA grants fast track status to Cocrystal’s norovirus drug - Investing.com
FDA Fast Track backs Cocrystal (Nasdaq: COCP) oral norovirus antiviral CDI-988 - Stock Titan
Cocrystal Pharma, Inc. announced that its antiviral candidate drug Cdi-988 has been granted Fast Track designation by the U.S. Food and Drug Administration (FDA). - Bitget
Cocrystal Pharma Receives FDA Fast Track Designation for CDI-988 for Norovirus Infection Treatment and Preventive - GlobeNewswire
COCP gets FDA Fast Track for CDI-988 norovirus drug, stock up 75% | Tap to know more | Inshorts - Inshorts
Cocrystal begins norovirus challenge study, reports 2025 results By Investing.com - Investing.com South Africa
Cocrystal Pharma Reports 2025 Financial Results and Advances Norovirus and Influenza Antiviral Drug Pipeline - Minichart
Cocrystal Pharma 2025 Research and Development Expenses $5.1M >COCP - Moomoo
Cocrystal Pharma Reports 2025 Financial Results, Advances Antiviral Drug Programs - National Today
Cocrystal Pharma Reports 2025 Financial Results - National Today
[10-K] Cocrystal Pharma, Inc. Files Annual Report - Stock Titan
Cocrystal begins norovirus challenge study, reports 2025 results - Investing.com
Cocrystal Pharma 2025 10-K: $0 Revenue, $(0.78) EPS, $(8.83)M Net Loss - TradingView
Cocrystal Pharma reports 2025 net loss $8.8M, cash $7.7M, advances norovirus CDI-988 into Phase 1b - TradingView — Track All Markets
Cocrystal Pharma, Inc. Reports Earnings Results for the Full Year Ended December 31, 2025 - marketscreener.com
Cocrystal Pharma (NASDAQ: COCP) cuts 2025 loss to $8.8M and advances antivirals - Stock Titan
Cocrystal Pharma, Inc. recently released its financial report for fiscal year 2025 and provided an update on the latest progress in its antiviral drug development projects. - Bitget
Cocrystal Pharma 2025 net loss narrows as R&D expenses fall - TradingView
BRIEF-Cocrystal Pharma FY Net Income USD -8.831 Million - TradingView — Track All Markets
No approved norovirus drug exists. Cocrystal now tests one in humans - Stock Titan
Institution Moves: Can Cocrystal Pharma Inc ride the EV waveEarnings Recap Report & Real-Time Volume Surge Alerts - baoquankhu1.vn
Cocrystal Pharma Inc Stock (COCP) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.69%
0.25%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):